ONCT 808
Alternative Names: ONCT-808; ROR1 CAR-T cell therapy; ROR1 targeted CAR-T therapy - Oncternal Therapeutics; ROR1-CAR-TLatest Information Update: 07 Jul 2025
At a glance
- Originator University of California, San Diego
- Developer Oncternal Therapeutics, Inc.
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued B-cell lymphoma; Solid tumours
Most Recent Events
- 27 Jun 2025 Hoola Therapeutics acquires ONCT 808 from Oncternal Therapeutics
- 07 Dec 2024 Efficacy, pharmacokinetics and adverse event data from a phase I/II trial in B-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 18 Sep 2024 Discontinued - Preclinical for Solid tumours in USA (Parenteral)